The Effect of Losartan on Emotional Processing in Healthy Volunteers

University of Oxford30 enrolled

Overview

This experimental medicine study explores whether a single dose of losartan (50mg) versus placebo affects the processing of positive and negative stimuli, using fMRI.

Losartan has been shown to accelerate fear extinction in animals and to prevent the development of anxiety disorders in humans, emphasising its potential to possibly enhance exposure therapy in humans. This study explores the basic effects of losartan on emotional processing, to identify neural mechanisms by which the drug might have synergistic effects on psychological treatment in humans. In a double-blind between-groups design, 30 healthy volunteers will be randomised to a group receiving a single dose of losartan (50mg) versus placebo, and this study will measure the effects of probing renin-angiotensin function on emotional information processing, using functional magnet resonance imaging (fMRI). Such knowledge will ultimately be essential for the development of more effective pharmaco-psychological treatment approaches for anxiety disorders.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Healthy Volunteers

Interventions

LosartanDRUG

blood pressure medication

PlaceboOTHER

non-active sham intervention

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * willing and able to provide informed consent * male or Female, aged 18-50 * body mass index (BMI) of 18-30 kg/m2 * fluent English skills * non- or light-smoker (\< 5 cigarettes a day) Exclusion Criteria: * Female participant who is pregnant or breast-feeding * central nervous system (CNS) active medication during the last 6 weeks * Current blood pressure/other heart medication (esp. aliskiren or beta blockers) * Intravascular fluid depletion * Past or present DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) axis-I diagnosis * Alcohol or substance abuse * First-degree family member with a history of a severe psychiatric disease * Impaired liver or kidney function * Lifetime history of epilepsy or other neurological disease, systemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study. * Insufficient English skills * participated in another study involving certain medication during last 6 weeks * Contraindication to magnet resonance imaging (MRI) scanning (e.g. pacemaker)

Outcomes

Primary Outcomes

BOLD signal change

BOLD signal change during functional magnet resonance imaging (fMRI)

Time frame: 1 day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.